Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 yrs, male or female subject~* Subjects must have signs and symptoms of PsA ≤5 years duration at the time of the Screening Visit~* SJC AND TJC must be \>1 and ≤ 4~* For all regions, the local Regulatory Label for treatment with apremilast must be followed.~* Stable doses of protocol-allowed PsA medications~* General good health (except for psoriatic arthritis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (Note: The definition of good health means a subject does not have uncontrolled significant comorbid conditions).~* Comply with protocol-required contraception measures~* Subject meets the Classification Criteria for Psoriatic Arthritis \[CASPAR\] Criteria for PsA at the Screening visit~Exclusion Criteria:~* Prior use of \>2 csDMARD to treat PsA~* Prior exposure to a JAK-inhibitor and/or a biologic DMARD.~* Use of intra-articular (IA) or intra-muscular (IM) glucocorticoid injection within 8 weeks before the Baseline Visit.~* Use of leflunomide within 12 weeks of randomization. Subjects who stopped leflunomide and completed 11 days of treatment with cholestyramine (8 g, 3 x daily) prior to the Baseline Visit may enter the study.~* Prior use of cyclosporine.~* Prior treatment with apremilast, or participation in a clinical study, involving apremilast.~* Use of any investigational drug within 4 weeks of the Baseline Visit, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 30 mg twice daily ± NSAIDs, ≤ 1 csDMARD (Type: EXPERIMENTAL): Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).